May 10, 2023
Crinetics Announces May 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics Pharmaceuticals announces May 2023 inducement grants: the stock options were granted as inducements material to nine employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4).
May 4, 2023
Crinetics Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
Crinetics Pharmaceuticals reported financial results and provided an update on first quarter 2023 clinical progress
April 9, 2023
Crinetics Announces April 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics Pharmaceuticals announces April 2023 inducement grants: the stock options were granted as inducements material to 15 employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4).
March 10, 2023
Crinetics Announces March 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics Pharmaceuticals announces March 2023 inducement grants: the stock options were granted as inducements material to eight employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4).
February 28, 2023
Crinetics Reports Fourth Quarter and Full Year 2022 Financial Results
Crinetics Pharmaceuticals reported financial results for the fourth quarter and year ended December 31, 2022